申请人:Pfizer Inc.
公开号:US04287341A1
公开(公告)日:1981-09-01
2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.
2,4-二氨基喹唑啉的化学式为##STR1##,其中Y.sup.1为氢或氯,Y.sup.2为OR,Y.sup.3为氢或OR,当Y.sup.1为氢时,Y.sup.3为OR,当Y.sup.1为氯时,Y.sup.3为氢或OR,以及其药用盐;R代表一个具有一至三个碳原子的烷基基团;单独取R.sup.1和R.sup.2分别为氢、具有一至五个碳原子的烷基、具有三至八个碳原子的环烷基、具有三至五个碳原子的烯基或炔基,或具有两至五个碳原子的羟基取代的烷基,当与它们连接的氮原子一起时,R.sup.1和R.sup.2形成一个取代或未取代的杂环基团,该基团可选地含有一个氧原子、硫原子或第二个氮原子作为环成员;它们作为降压药剂的用途,含有它们的药物组合物以及它们生产的中间体。